Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, is pleased to announce that it has entered into two separate letters of intent with companies specialized in pharmaceutical API manufacturing. Pursuant to the agreements, these companies will carry-out under contract the commercial scale-up of specific steps of Bioxel's manufacturing process for semi-synthetic taxanes.
